These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35661567)

  • 1. Hiding in plain sight: The magnitude of unused disease modifying therapies in multiple sclerosis and strategies for reducing the economic burden of care.
    Okuda DT; Burgess KW; Cook K; McCreary M; Winkler MD; Moog TM
    Mult Scler Relat Disord; 2022 Jul; 63():103920. PubMed ID: 35661567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy.
    Kozlicki MZ; Markley B; Shah NB; DeClercq J; Choi L; Zuckerman AD
    Mult Scler Relat Disord; 2022 Jul; 63():103860. PubMed ID: 35609353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis.
    Zuckerman AD; DeClercq J; Simonson D; Zagel AL; Turco E; Banks A; Wawrzyniak J; Rightmier E; Blevins A; Choi L
    Mult Scler Relat Disord; 2023 Jul; 75():104738. PubMed ID: 37182475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns and persistence on disease modifying therapies for multiple sclerosis and its associated factors.
    Cárdenas-Robledo S; Arenas-Vargas LE; Arenas RD; Gaspar-Toro JM; Muñoz-Rosero ÁM; Tafur-Borrero AH; Marín-Medina DS; Acosta-Fajardo HA; Guío-Sánchez C; López-Reyes L
    BMC Neurol; 2024 Apr; 24(1):108. PubMed ID: 38566012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States.
    Bin Sawad A; Seoane-Vazquez E; Rodriguez-Monguio R; Turkistani F
    Curr Med Res Opin; 2016 Nov; 32(11):1783-1788. PubMed ID: 27359262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression.
    Mardan J; Hussain MA; Allan M; Grech LB
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1273-1295. PubMed ID: 34464209
    [No Abstract]   [Full Text] [Related]  

  • 7. Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of Multiple Sclerosis DMTs: A Systematic Review.
    Onuorah HM; Charron O; Meltzer E; Montague A; Crispino A; Largent A; Lucas A; Freeman L
    Neurology; 2022 Mar; 98(9):e880-e892. PubMed ID: 35046135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
    Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
    Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
    Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.
    Frahm N; Ellenberger D; Stahmann A; Fneish F; Lüftenegger D; Salmen HC; Schirduan K; Schaak TPA; Flachenecker P; Kleinschnitz C; Paul F; Krefting D; Zettl UK; Peters M; Warnke C
    Ther Adv Neurol Disord; 2024; 17():17562864241239740. PubMed ID: 38560408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden.
    Teni FS; Machado A; Murley C; He A; Fink K; Gyllensten H; Glaser A; Alexanderson K; Hillert J; Friberg E
    Mult Scler Relat Disord; 2023 Jan; 69():104456. PubMed ID: 36529068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
    Freeman L; Kee A; Tian M; Mehta R
    Drugs Real World Outcomes; 2021 Dec; 8(4):497-508. PubMed ID: 34136997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparities in DMT treatment: Demographic and neurocognitive differences between MS patients currently treated versus not treated with disease-modifying therapies.
    Leavitt VM; Dworkin JD; Galioto R; Ratzan AS
    Mult Scler Relat Disord; 2024 May; 85():105508. PubMed ID: 38452646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to Disease-Modifying Therapies for Multiple Sclerosis.
    Higuera L; Carlin CS; Anderson S
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1394-1401. PubMed ID: 27882830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
    Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA.
    Hartung DM
    Curr Neurol Neurosci Rep; 2021 May; 21(7):28. PubMed ID: 33948740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of treatment switching in the Big Multiple Sclerosis Data Network.
    Spelman T; Magyari M; Butzkueven H; Van Der Walt A; Vukusic S; Trojano M; Iaffaldano P; Horáková D; Drahota J; Pellegrini F; Hyde R; Duquette P; Lechner-Scott J; Sajedi SA; Lalive P; Shaygannejad V; Ozakbas S; Eichau S; Alroughani R; Terzi M; Girard M; Kalincik T; Grand'Maison F; Skibina O; Khoury SJ; Yamout B; Sa MJ; Gerlach O; Blanco Y; Karabudak R; Oreja-Guevara C; Altintas A; Hughes S; McCombe P; Ampapa R; de Gans K; McGuigan C; Soysal A; Prevost J; John N; Inshasi J; Stawiarz L; Manouchehrinia A; Forsberg L; Sellebjerg F; Glaser A; Pontieri L; Joensen H; Rasmussen PV; Sejbaek T; Poulsen MB; Christensen JR; Kant M; Stilund M; Mathiesen H; Hillert J;
    Front Neurol; 2023; 14():1274194. PubMed ID: 38187157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to second line MS disease-modifying therapies is associated with decreased relapse rate.
    Marriott JJ; Ekuma O; Fransoo R; Marrie RA
    Front Neurol; 2023; 14():1243589. PubMed ID: 37745666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.